A Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Canopy Growth Corporation (WEED) received a Buy rating from CIBC’s analyst John Zamparo, with a C$75 price target.
Zamparo has an average return of 8.6% when recommending Canopy Growth Corporation.
According to TipRanks.com, Zamparo is ranked #4507 out of 5180 analysts.
Read also: Tilray (TLRY) Ramping up Cannabis Supply in Canada with Acquisition of Natura Naturals Holdings
Canopy Growth Corporation has an analyst consensus of Strong Buy, with a price target consensus of C$70, implying a 15.2% upside from current levels. In a report issued on February 5, Piper Jaffray also reiterated a Buy rating on the stock.
.
Canopy Growth Corporation’s market cap is currently C$14.05B and has a P/E ratio of 0. The company has a Price to Book ratio of 8.61.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules, and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite.
The company’s shares closed on Tuesday at C$60.75.
